Thalys Medical Technology Group Inc. (603716.SS)
CNY 10.69
(3.89%)
CNY 10.69
(3.89%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 389.73 Million CNY | -14.36% |
| 2022 | 458.56 Million CNY | -16.3% |
| 2021 | 547.86 Million CNY | 11.22% |
| 2020 | 492.58 Million CNY | -5.49% |
| 2019 | 521.21 Million CNY | 24.69% |
| 2018 | 417.99 Million CNY | 34.8% |
| 2017 | 310.07 Million CNY | 41.92% |
| 2016 | 218.48 Million CNY | 16.68% |
| 2015 | 187.24 Million CNY | 14.46% |
| 2014 | 163.59 Million CNY | 12.24% |
| 2013 | 145.74 Million CNY | 35.58% |
| 2012 | 107.5 Million CNY | 29.78% |
| 2011 | 82.83 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 94.51 Million CNY | 34.14% |
| 2024 Q1 | 110.1 Million CNY | 41.74% |
| 2024 Q2 | 70.45 Million CNY | -36.01% |
| 2023 Q3 | 91.44 Million CNY | -26.52% |
| 2023 FY | 392.69 Million CNY | -14.36% |
| 2023 Q1 | 99.11 Million CNY | 59.23% |
| 2023 Q2 | 124.45 Million CNY | 25.57% |
| 2023 Q4 | 77.68 Million CNY | -15.05% |
| 2022 Q2 | 116.85 Million CNY | -20.18% |
| 2022 Q1 | 146.4 Million CNY | -15.78% |
| 2022 FY | 458.56 Million CNY | -16.3% |
| 2022 Q4 | 62.24 Million CNY | -53.22% |
| 2022 Q3 | 133.06 Million CNY | 13.87% |
| 2021 Q2 | 141.93 Million CNY | 24.57% |
| 2021 Q3 | 118.16 Million CNY | -16.74% |
| 2021 Q1 | 113.93 Million CNY | -27.84% |
| 2021 FY | 547.86 Million CNY | 11.22% |
| 2021 Q4 | 173.82 Million CNY | 47.1% |
| 2020 Q2 | 136.05 Million CNY | 133.96% |
| 2020 Q1 | 58.15 Million CNY | -54.5% |
| 2020 FY | 492.58 Million CNY | -5.49% |
| 2020 Q4 | 157.88 Million CNY | 12.38% |
| 2020 Q3 | 140.49 Million CNY | 3.26% |
| 2019 Q2 | 148.61 Million CNY | 43.17% |
| 2019 FY | 521.21 Million CNY | 24.69% |
| 2019 Q3 | 140.97 Million CNY | -5.14% |
| 2019 Q4 | 127.81 Million CNY | -9.33% |
| 2019 Q1 | 103.8 Million CNY | -9.8% |
| 2018 Q3 | 109.12 Million CNY | 1.49% |
| 2018 Q2 | 107.52 Million CNY | 24.65% |
| 2018 Q1 | 86.26 Million CNY | -19.56% |
| 2018 FY | 417.99 Million CNY | 34.8% |
| 2018 Q4 | 115.07 Million CNY | 5.45% |
| 2017 Q4 | 107.23 Million CNY | 21.43% |
| 2017 Q3 | 88.31 Million CNY | 41.61% |
| 2017 Q2 | 62.36 Million CNY | 19.56% |
| 2017 Q1 | 52.16 Million CNY | -14.11% |
| 2017 FY | 310.07 Million CNY | 41.92% |
| 2016 Q3 | 56.09 Million CNY | -1.9% |
| 2016 FY | 218.48 Million CNY | 16.68% |
| 2016 Q4 | 60.73 Million CNY | 8.27% |
| 2016 Q2 | 57.17 Million CNY | 13.27% |
| 2016 Q1 | 50.47 Million CNY | -6.05% |
| 2015 Q4 | 53.73 Million CNY | 8.79% |
| 2015 FY | 187.24 Million CNY | 14.46% |
| 2015 Q3 | 49.39 Million CNY | 0.0% |
| 2014 FY | 163.59 Million CNY | 12.24% |
| 2013 FY | 145.74 Million CNY | 35.58% |
| 2012 FY | 107.5 Million CNY | 29.78% |
| 2011 FY | 82.83 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 2.41 Billion CNY | 83.886% |
| Joinn Laboratories(China)Co.,Ltd. | 1.01 Billion CNY | 61.518% |
| WuXi AppTec Co., Ltd. | 16.27 Billion CNY | 97.606% |
| Autobio Diagnostics Co., Ltd. | 2.83 Billion CNY | 86.237% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 3.11 Billion CNY | 87.489% |
| Chemclin Diagnostics Co., Ltd. | 335.61 Million CNY | -16.125% |